Vivos Inc (RDGL)

[Roofus]

Over one million thyroid cancer cases per year worldwide.

Of which, nearly 50,000 thyroid cancer cases per year in the United States.

But over a million new thyroid cancer cases per year worldwide.
And RadioGel has a patent in nearly every major nation in the world.

Let’s say RadioGel is treated on just 200,000 of those 1,000,000+ cases per year.
That’s roughly 20%.

200,000 cases multiplied by $10,000 revenue per case = $2 billion in revenue per year.
Multiplied by a generic 5x multiplier to get a market cap valuation = $10 billion market cap value.

$10 billion / 300 million outstanding shares = $33 per share.

Major Pharma is most certainly going to offer to buy this technology for at least $3 billion.
That sort of buyout means our shares will be bought out for around $10.00+ per share.